Business Description
Inhibikase Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45719W2052
Share Class Description:
FRA:IQT0: Ordinary SharesDescription
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 46.65 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -22 | |||||
| 3-Year EPS without NRI Growth Rate | -19.3 | |||||
| 3-Year FCF Growth Rate | -60.2 | |||||
| 3-Year Book Growth Rate | -32.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.17 | |||||
| 9-Day RSI | 39.35 | |||||
| 14-Day RSI | 43.86 | |||||
| 6-1 Month Momentum % | -21.9 | |||||
| 12-1 Month Momentum % | -41.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 2.55 | |||||
| Cash Ratio | 2.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -54.6 | |||||
| Shareholder Yield % | -2.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -123.78 | |||||
| ROA % | -102.17 | |||||
| ROIC % | -2064.42 | |||||
| ROC (Joel Greenblatt) % | -5646.22 | |||||
| ROCE % | -128.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.73 | |||||
| Price-to-Tangible-Book | 1.73 | |||||
| EV-to-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.11 | |||||
| EV-to-Forward-Revenue | 1358.04 | |||||
| EV-to-FCF | -0.14 | |||||
| Price-to-Net-Current-Asset-Value | 1.79 | |||||
| Price-to-Net-Cash | 2.15 | |||||
| Earnings Yield (Greenblatt) % | -909.09 | |||||
| FCF Yield % | -136.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inhibikase Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.025 | ||
| Beta | 0 | ||
| Volatility % | 99.79 | ||
| 14-Day RSI | 43.86 | ||
| 14-Day ATR (€) | 0.002651 | ||
| 20-Day SMA (€) | 3.21 | ||
| 12-1 Month Momentum % | -41.21 | ||
| 52-Week Range (€) | 2.555999 - 5.609999 | ||
| Shares Outstanding (Mil) | 5.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibikase Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibikase Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inhibikase Therapeutics Inc Frequently Asked Questions
What is Inhibikase Therapeutics Inc(FRA:IQT0)'s stock price today?
The current price of FRA:IQT0 is €3.21. The 52 week high of FRA:IQT0 is €5.61 and 52 week low is €2.56.
When is next earnings date of Inhibikase Therapeutics Inc(FRA:IQT0)?
The next earnings date of Inhibikase Therapeutics Inc(FRA:IQT0) is 2024-08-14 Est..
Does Inhibikase Therapeutics Inc(FRA:IQT0) pay dividends? If so, how much?
Inhibikase Therapeutics Inc(FRA:IQT0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers